PDCD1 and non-small cell lung carcinoma: Notably, nivolumab, an anti‐PD‐1 monoclonal antibody, with ipilimumab, an anti‐CTLA‐4 monoclonal antibody, has shown substantial improvements and is recommended as a first‐line treatment for patients with advanced NSCLC (Table 2) [67, 68].